- CSR Summary Not Yet Available
- NCT01483599
- Primary Citation
Trial Information
Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaSkin and Connective Tissue DiseasesEnrollment293% Female28.4%% White90.9%
Product ClassAntipsoriaticsSponsor Protocol NumberCNTO1959PSO2001Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)44
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0808 : Making Effectiveness Research better by meta-analysing Trial and Real World Evidence in Immune-Mediated inflammatory Diseases (MERMAID)
- 2022-4894 : Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of RCTs
- 2015-0339 : Impact of the dose of immunomodulators on pharmacokinetics of biologics: Patient level meta-analysis of randomized controlled trials